Introduction {#Sec1}
============

Psoriasis is a chronic, inflammatory systemic disease typically characterized by erythematous, scaly patches, or plaques on the skin resulting from hyperproliferation of epidermal keratinocytes \[[@CR1], [@CR2]\]. The disorder affects approximately 1--3 % of the world population \[[@CR3]--[@CR6]\]. Psoriatic arthritis (PsA) is a spondyloarthritic condition, which is present in up to 42 % of individuals with psoriasis and has an estimated prevalence of 0.1--1.0 % in the general population \[[@CR7]\]. PsA is characterized by synovitis, enthesitis, dactylitis and spondylitis \[[@CR8], [@CR9]\]. Psoriasis and PsA share common pathophysiologic mechanisms (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR10]--[@CR14]\]; nearly all individuals with PsA also have psoriasis \[[@CR10]\].Fig. 1Shared attributes of cutaneous psoriasis and psoriatic arthritis \[[@CR10]--[@CR14]\]. *AP* activator protein, *CPII* C-propeptide of type II collagen, *C2C* collagen fragment neoepitopes Col2-3/4C~long\ mono~, *HLA* human leukocyte antigen, *hsCRP* highly sensitive C-reactive protein, *IFN* interferon, *IL* interleukin, *IL-12B* interleukin 12 beta, *IL-23r* interleukin 23 receptor, *MAPK* mitogen-activated protein kinase, *MMP* matrix metalloproteinase, *NF* nuclear factor, *OPG* osteoprotegerin, *pDC* precursor dendritic cell, *RANK* receptor activator of NF-κB, *TNF* tumour necrosis factor

Between 6 and 42 % of patients with psoriasis will develop PsA \[[@CR8]\], although lower estimates may reflect a missed diagnosis or misdiagnosis \[[@CR7], [@CR15], [@CR16]\]. In a study that assessed the prevalence and clinical pattern of PsA in 1,511 patients with psoriasis, 312 (21 %) had existing PsA and 85 % of these cases had been diagnosed for the first time during the study \[[@CR17]\]. In a more recent study, 949 psoriasis patients seen serially in dermatology clinics were subsequently evaluated by rheumatologists; 30 % were diagnosed with PsA and 41 % of these had not been aware of the diagnosis \[[@CR18]\]. PsA is often undiagnosed or misdiagnosed. Skin disease generally precedes joint disease in the majority (≈75--80 %) of patients, with a typical lag time of about 7--12 years from the onset of psoriasis to diagnosis of PsA \[[@CR3], [@CR7], [@CR15], [@CR19]\]. Thus, routinely screening psoriasis patients for PsA in the dermatology clinic is important, as most patients with PsA will present to a dermatologist first, long before joint symptoms emerge. However, in 10--15 % of cases, PsA may precede psoriasis \[[@CR10]\].

Patients with psoriasis, PsA or both generally have reduced health-related quality of life (QOL), productivity and functionality similar to those of patients with other serious diseases, such as cancer, heart disease and diabetes \[[@CR20]--[@CR30]\]. In addition, PsA has been associated with long-term work disability, loss of productivity and work absenteeism \[[@CR24]--[@CR27]\]. The burden of illness associated with PsA in patients with psoriasis has been reviewed \[[@CR31], [@CR32]\]. Individuals with both psoriasis and PsA may experience emotional distress and discomfort caused by skin involvement and pain, and physical limitations caused by joint involvement, which could synergistically affect their QOL \[[@CR17], [@CR33], [@CR34]\]. Compared with psoriasis patients who do not have PsA, psoriasis patients with PsA have greater QOL impairment, including physical and mental components of the 36-Item Short Form Health Survey \[[@CR32], [@CR34]\]. In addition, patients may have difficulty determining the appropriate provider for diagnosis and management of their PsA, and patients may lack understanding regarding their treatment options. Because most patients will be treated first for the skin lesions associated with psoriasis, dermatologists are in a unique position to screen for and diagnose early PsA \[[@CR3], [@CR35], [@CR36]\].

Pathophysiology {#Sec2}
===============

Genetic Variations in Psoriasis and PsA {#Sec3}
---------------------------------------

About 40 years ago, Moll and Wright reported that first-degree relatives of individuals with PsA had a 19-fold increase in psoriasis prevalence compared with the general population \[[@CR37]\]. Investigations into the genetic basis of psoriasis and PsA have revealed commonalities as well as distinctions between the two disease processes. Considerable overlap exists in human leukocyte antigens (HLAs) associated with both diseases (e.g. B13, B17, B57, Cw6 and DR7) \[[@CR10], [@CR38]\]. The tumour necrosis factor (TNF)-α locus, TNF-238, and the NOD2/PSORAS1 locus on chromosome 16q, which corresponds to a variant in the CARD15 domain previously shown to increase susceptibility to Crohn's disease, have been identified as regions that may predispose patients to both psoriasis and PsA \[[@CR10], [@CR39]--[@CR41]\], although findings have been inconclusive \[[@CR42]\]. Interleukin (IL)-12 beta and IL-23 receptor are also associated with both psoriasis and PsA \[[@CR38], [@CR43]--[@CR45]\]. Although the evidence is preliminary and research is ongoing, certain single-nucleotide polymorphisms have been related to PsA and clinical subphenotypes \[[@CR46], [@CR47]\]. In one such study, Jadon and colleagues \[[@CR46]\] detected a strong predictive relationship between an IL-12 beta variant and the presence of PsA; they also detected a trend towards a relationship between an IL-23 receptor variant and erosive peripheral joint disease.

Genetic differences between psoriasis and PsA are also being identified. A recent study showed that psoriasis is more closely associated with HLA-C alleles and PsA is more closely associated with HLA-B alleles, including HLA B\*27 and B\*39 \[[@CR11], [@CR48]\]. PSORS1 on chromosome 6p and PSORS2 on chromosome 17q have been confirmed as loci for genetic susceptibility to psoriasis \[[@CR10]\]. However, these loci have not shown a reproducible association with PsA \[[@CR10], [@CR49]\]. Mapping of the major histocompatibility complex has identified several novel loci for PsA that are independent of known HLA susceptibility alleles \[[@CR50]\]. A recent study found that the frequency of C\*06:02 was lower in patients with PsA (28.7 %) than in those with psoriasis (57.5 %) \[[@CR11]\]. Two separate clinical patterns of major histocompatibility complex effect have been identified; C\*06 was associated with more penetrant skin disease and less prevalent musculoskeletal disease, while an HLA-B (B\*27) phenotype was associated with more prevalent musculoskeletal disease \[[@CR11]\]. Together, the available evidence shows that the genetic aetiology of psoriasis and PsA is complex and appears to be based on multiple shared and unshared genetic factors as well as environmental stimuli \[[@CR10], [@CR51]\].

Inflammatory Processes and Mediators in Psoriasis and PsA {#Sec4}
---------------------------------------------------------

Psoriasis and PsA show significant similarities in inflammatory processes and mediators. The immune system is normally homeostatic, with mechanisms in place to turn off an immune response and avoid tissue damage associated with chronic inflammation \[[@CR52]\]. Cyclic adenosine monophosphate (cAMP), a naturally occurring secondary messenger, helps maintain homeostasis by modulating the network of pro-inflammatory and anti-inflammatory mediators \[[@CR53]\]. cAMP levels are regulated by phosphodiesterases (PDEs), intracellular enzymes that convert cAMP to AMP \[[@CR53]\]. In immune cells, PDE4 is the predominantly active PDE \[[@CR54]\]. The conversion of cAMP to AMP leads to increased pro-inflammatory mediator production and decreased anti-inflammatory mediator production \[[@CR53]\]. Increased levels of pro-inflammatory mediators are found in psoriatic lesions and the synovium of patients with PsA \[[@CR55]--[@CR61]\].

Pro-inflammatory mediators that drive psoriasis and PsA are released by a variety of cell types, including innate immune cells, adaptive immune cells and resident immune cells (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR1], [@CR57]\]. Plasmacytoid dendritic cells act as regulators of innate and active immune responses and play a pivotal role in T cell-mediated immune responses \[[@CR1], [@CR62], [@CR63]\]. Large numbers of plasmacytoid dendritic cells are found in psoriatic skin and psoriatic synovium \[[@CR10]\]. Activated dendritic cells present antigens and produce interferon (IFN)-α and pro-inflammatory mediators, such as IL-12 and IL-23 \[[@CR1]\]. T cells respond to antigen presented by myeloid dendritic cells by proliferating and differentiating into type 1 and type 17 T helper cells, which increase the secretion of inflammatory cytokines \[[@CR1]\]. In one study, messenger RNA (mRNA) levels of the T cell regulatory cytokine IL-7, which stimulates production of pro-inflammatory cytokines, were increased in the synovial fluid of patients with spondyloarthritis \[[@CR64]\]. CD11+ dendritic cells express nitric oxide synthase and TNF-α \[[@CR65]\], and CD8+ and CD4+ T cells produce IFN-γ, TNF-α and IL-2 \[[@CR66]\].Fig. 2Mechanisms of systemic, chronic inflammation in psoriasis and psoriatic arthritis. From Nestle et al. \[[@CR1]\]. Copyright © 2009, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. *CCL* chemokine (C-C motif) ligand, *CXCL* chemokine (C-X-C motif) ligand, *Th* T helper, *TNF* tumour necrosis factor

Activated dendritic cells and associated inflammatory signalling molecules also exert effects on other cell types, including keratinocytes, leukocytes, neutrophils, endothelial cells and vascular smooth muscle cells, marked by chemotaxis, proliferation and production of additional inflammatory mediators \[[@CR63]\]. Chronic disruptions in inflammatory signalling are believed to lead to lasting changes in resident cells of the skin and joints, which underlie the clinical hallmarks of psoriatic disease \[[@CR1], [@CR67]\]. Angiogenesis is another common but less often recognized feature of both psoriasis and PsA \[[@CR8], [@CR68]\]. Angiogenic markers, such as vascular endothelial growth factor (VEGF), placental growth factor, VEGF receptor 2 and neuropilin-1, are increased in psoriatic disease \[[@CR67]\]. Chronic inflammatory signalling also plays a role in psoriatic joint disease. Circulating levels of Dikkopf-1 and macrophage colony stimulating factor, both soluble mediators of bone remodelling, have been found to be higher in PsA patients than in psoriasis patients and healthy controls; levels of these mediators have been correlated with radiographic progression \[[@CR69]\].

Clinical Features of PsA and Screening {#Sec5}
======================================

Dermatologists play an important role in screening and diagnosing patients with early PsA. Active monitoring of psoriasis patients for signs of joint or arthritic involvement and familiarity with PsA screening, diagnosis and treatment options can help dermatologists positively impact the clinical course of psoriatic disease \[[@CR3], [@CR8], [@CR35], [@CR36]\]. Irreversible joint damage and PsA progression begin within the first 2 years after disease onset, with an increase in the number of joints affected over time; thus, routine screening in the dermatology clinic can be key to early detection \[[@CR8], [@CR36], [@CR70]--[@CR72]\]. Early intervention in the PsA disease process can inhibit or delay structural joint damage, and patients are more likely to experience improvements in pain, fatigue, depression and QOL \[[@CR8], [@CR35], [@CR72]\].

Because the symptoms of PsA may overlap with those of many other inflammatory and rheumatologic conditions, including osteoarthritis, rheumatoid arthritis (RA) and other spondyloarthritic conditions \[[@CR36]\], PsA is often misdiagnosed (Table [1](#Tab1){ref-type="table"}) \[[@CR8], [@CR73]--[@CR81]\]. Alternatively, a patient may not consider it relevant or appropriate to mention musculoskeletal symptoms to a dermatologist and may assume that the symptoms will resolve or that there is nothing to be done for them, thus leading to inattention. PsA diagnosis is further complicated by the broad range of potential musculoskeletal symptoms and an often waxing-and-waning clinical course \[[@CR8]\]. To identify patients who may have PsA, dermatologists can routinely ask psoriasis patients about key signs/symptoms of PsA, including whether they have experienced morning stiffness in joints lasting longer than 30 min, swelling in a finger or toe, or nail changes. A number of screening tools have been developed for diagnosis of PsA (Table [2](#Tab2){ref-type="table"}) \[[@CR82]--[@CR88]\], several of which show good sensitivity or specificity in the setting of dermatology clinics or general medical clinics. If PsA is suspected, referral to a rheumatologist should be considered, depending on the dermatologist's comfort level with managing PsA \[[@CR8], [@CR15], [@CR89]\].Table 1Differential diagnosis of psoriatic arthritis (PsA) versus other rheumatic disease conditions \[[@CR8], [@CR73]--[@CR81]\]Clinical featurePsAOsteoarthritisFibromyalgiaGoutAnkylosing spondylitisPsoriasis+−−−−Nail dystrophy+−−−−Enthesitis+−++Less oftenDactylitis+−−+Less oftenPeripheral joint++++−Axial joint/spondylitis+−++, less often+Stiffness++, with mobility+++Rheumatoid factor positive^a^−−−−−^a^The diagnostic utility of rheumatoid factor alone is limited because a proportion of healthy individuals can be rheumatoid factor positive and, infrequently, rheumatoid factor can be positive in patients with PsA. Therefore, detection of rheumatoid factor should not be used alone in diagnosis of these conditions but used in conjunction with other clinical and assessment factors \[[@CR73], [@CR74], [@CR90], [@CR201]\]Table 2Psoriatic arthritis (PsA) screening toolsNameOverviewCommentsCurrent tools PASQ \[[@CR82]\]10 items + joint diagram\
Self-report PASE \[[@CR84]\]Self-administered\
15 items\
Maximum score: 75Threshold score = 47\
Sensitivity 82 %\
Specificity 73 % PEST \[[@CR85]\]Self-administered\
5 items + joint diagram\
Maximum score: NAThreshold score = 3\
Sensitivity 97 %\
Specificity 79 % ToPAS \[[@CR86]\]Self-administered\
11 items + pictures/diagram\
Maximum score: NAThreshold score = 8\
Sensitivity 86.8 %\
Specificity 93.1 %\
ToPAS II is available online (see <http://www.ibridgenetwork.org/uhn/toronto-psoriatic-arthritis-screen-ii-topas-ii)>Tools in development ePASQ \[[@CR87]\]10 items + joint diagram\
Self-report\
*Exact match of paper version*Electronic application is available online (see <http://www.nlrt.ca/screenTool.html)> EARP \[[@CR88]\]Self-administered\
14 questionsSensitivity 85.2 %\
Specificity 91.6 %*EARP* Early Arthritis for Psoriatic Patients, *ePASQ* Electronic Psoriatic Arthritis Screening Questionnaire, *NA* not applicable, *PASE* Psoriatic Arthritis Screening and Evaluation, *PASQ* Psoriatic Arthritis Screening Questionnaire, *PEST* Psoriasis Epidemiology Screening Tool, *ToPAS* Toronto Psoriatic Arthritis Screening

Patient Assessment, Staging and Treatment Plan {#Sec6}
==============================================

Assessment and Staging {#Sec7}
----------------------

Patients in whom there is a strong suspicion of PsA, based on clinical presentation of arthritis, enthesitis, dactylitis and/or spondylitis (pain, swelling, tenderness, stiffness), should undergo a more thorough examination. The Classification Criteria for Psoriatic Arthritis (CASPAR) \[Table [3](#Tab3){ref-type="table"}\] were developed as *classification criteria* for the purpose of identifying standardized groups of PsA subjects for research where specificity is most important---not as individual *diagnostic criteria*, wherein sensitivity is paramount \[[@CR90]\]. Nonetheless, clinicians may find utility in applying the elements of CASPAR when considering a diagnosis of PsA. CASPAR bases diagnosis on clinical presentation, history and radiographic and laboratory evidence, and exhibits 99 % specificity for classification of PsA \[[@CR75], [@CR90]\]. The *stem* of the criteria requires clinician judgment that the patient has *inflammatory* arthritis, enthesitis and/or spondylitis; if this stem is fulfilled, then the other elements of the criteria can be applied. Inflammatory features of PsA include stiffness, pain, swelling and tenderness of the joints, ligament and tendon insertions into bone (enthesitis), and spine, and dactylitis (swelling of an entire digit). The severity and pattern (e.g. symmetrical versus asymmetrical, monoarticular versus polyarticular) of peripheral and axial joint disease vary widely among patients \[[@CR8]\]. Enthesitis may be one of the earliest signs of PsA \[[@CR91]\]. Dactylitis occurs in up to 50 % of patients with PsA and is a marker for disease progression \[[@CR92]\]. Spondylitis, characterized by inflammation in joints, entheses and bones of the spine and sacroiliac joints, may occur in a significant proportion of PsA patients \[[@CR91]\]. PsA is characterized by joint erosions, joint space narrowing, bony proliferation, osteolysis (e.g. pencil-in-cup deformity), acro-osteolysis, ankylosis, spur formation and spondylitis on radiographs \[[@CR8], [@CR90], [@CR93]\]. PsA patients are typically seronegative for rheumatoid factor \[[@CR10], [@CR74], [@CR90], [@CR94]\].Table 3Classification Criteria for Psoriatic Arthritis (CASPAR) \[[@CR90]\]Symptom domainCriterion^a^ClinicalEstablished inflammatory articular diseaseCurrent psoriasis or history of psoriasis (personal or family)Dactylitis (current or history)Psoriatic nail dystrophyRadiologyJuxta-articular new bone formationSerologyRheumatoid factor negative^a^CASPAR point values: current psoriasis is assigned a score of 2; all other features are assigned a score of 1. To meet the criteria, patients must score at least 3 points from the five categories

Controversy exists as to whether psoriatic nail involvement is predictive of PsA. Approximately 45 % of psoriasis patients have characteristic psoriatic nail pitting, onycholysis and hyperkeratosis but do not have concurrent PsA \[[@CR7]\]. Nevertheless, nail dystrophy appears to be a clinically valuable marker that should raise suspicion of psoriatic joint disease. In a cohort study of 1,593 patients with psoriasis, nail dystrophy was a significant predictor of co-existing PsA (hazard ratio 2.93, 95 % confidence interval 1.68--5.12) \[[@CR95]\]. Nail involvement can also help distinguish between PsA and RA, a condition where nail dystrophy does not occur \[[@CR7], [@CR96]\]. Currently, CASPAR includes psoriatic nail dystrophy among the criteria for PsA \[[@CR90]\].

Even when PsA appears likely, differential diagnosis of PsA versus other arthritic and rheumatologic conditions should be considered \[[@CR8], [@CR74], [@CR76], [@CR97]\]. This can be challenging, given the many overlapping clinical features among these conditions (Table [1](#Tab1){ref-type="table"}) \[[@CR8], [@CR73]--[@CR81]\]. Hallmark clinical features differentiating PsA from other, similar arthropathies include the presence of psoriatic skin involvement in nearly all cases, nail dystrophy and dactylitis. Diagnostic laboratory markers for PsA are lacking, and those used to date have typically helped differentiate PsA from other conditions rather than specifically diagnosing PsA \[[@CR98]\]. Evaluation of the erythrocyte sedimentation rate and C-reactive protein level has limited utility in diagnosis of PsA, as these markers have been shown to be elevated in only about half of the patients with PsA; however, in PsA patients who do have an elevated erythrocyte sedimentation rate and elevated C-reactive protein levels, they are useful to assess disease activity and thus worthwhile to assess in patients who are suspected to have PsA.

Antibodies to cyclic citrullinated peptides, which are present in up to 13 % of PsA patients, have also been evaluated; although their utility in diagnosis is uncertain, evidence suggests that this marker may be useful in identifying patients with erosive features and multiple joint involvement \[[@CR99]\]. When evaluating patients with suspected PsA, imaging studies are important tools. In addition to radiography, which is the primary method used, ultrasound has been recommended as an imaging tool to evaluate joint inflammation in patients with suspected PsA \[[@CR100]\].

Assessment tools used by rheumatologists to stage and treat patients with PsA have been adapted from measures used in RA and include global assessment questionnaires and examination of small and large joints, entheses and digits, including a swollen and tender joint count. An overall assessment of the skin and nails is also performed \[[@CR8], [@CR9], [@CR101], [@CR102]\]. Adequate assessment of disease severity and risk of progression is key to making sound treatment decisions. In clinical trials and registries, baseline PsA severity and response to treatment are currently gauged by American College of Rheumatology (ACR) and Disease Activity Score (DAS) criteria defined for RA on the basis of tender and swollen joint counts, as well as individual measures of enthesitis and dactylitis \[[@CR102]\]. New PsA-specific composite indices, which assess varying combinations of joint involvement, skin involvement, disease activity, pain, health-related QOL and functional impact---such as the Composite Disease Activity Index (CPDAI), PsA Disease Activity Score (PSADAS) and Arithmetic Mean of Desirability Functions (AMDF)---have recently been developed, and their psychometric properties are being evaluated \[[@CR102], [@CR103]\]. Risk of disease progression is judged on the basis of history and initial clinical presentation. Patients presenting with established PsA for more than 2 years are at relatively greater risk of disease progression (i.e. clinical damage) than those with a shorter history of joint involvement \[[@CR91]\]. Other recognized predictors of disease progression are baseline joint damage, baseline acute-phase reactants, polyarticular presentation and the number of inflamed joints at each visit \[[@CR104]\].

Ideally, dermatologists initiate treatment with a medication that is effective for both psoriasis and PsA, while considering proven efficacy in axial disease and clinical features such as enthesitis and dactylitis. Alternatively, referral to a rheumatologist for treatment should occur, especially if the PsA manifestations are not responding adequately. Recently, the European League Against Rheumatism (EULAR) established a PsA treatment algorithm (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR89]\]. This algorithm may serve as a guide for dermatologists in defining appropriate treatment options for psoriatic disease to optimally manage these patients, whether they are treating them alone or in conjunction with a rheumatologist. The long-term goals of the EULAR algorithm are to maintain health-related QOL, limit skin and joint signs and symptoms, and prevent or slow structural damage \[[@CR89]\]. For patients with active PsA, initial treatment with a traditional disease-modifying anti-rheumatic drug (DMARD) should be considered; if the response is inadequate, an anti-TNF-α biologic agent should be considered \[[@CR89]\] (Table [4](#Tab4){ref-type="table"} \[[@CR2], [@CR105]--[@CR128]\]). According to EULAR recommendations, initial treatment with an anti-TNF-α biologic agent may be prudent for patients with extensive involvement of skin and joints \[[@CR89]\]. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has also published international treatment recommendations for PsA \[[@CR129]\], which are currently in the process of being updated. These guidelines take into account each of the key clinical domains of PsA (arthritis, enthesitis, dactylitis, spondylitis and skin disease) and encourage the clinician to evaluate the patient comprehensively in the treatment algorithm, in terms of both the clinical severity of each domain and the impact on function and QOL.Fig. 3European League Against Rheumatism (EULAR) recommended treatment algorithm for management of psoriatic arthritis. The recommendations have been divided into four phases. Small fonts within the ellipses in phases II and III refer to dose modifications or an alternative therapy, as detailed within the body of the recommendations. ^a^Because of the variable nature of the disease, not all situations can be covered by this figure; therefore, it is important to consult the full text to which the *numbers* or *letters in parentheses* refer; *dotted lines* refer to situations where deleting a phase is recommended. ^b^Active disease: ≥1 tender and inflamed joint and/or tender enthesis point, and/or dactylitic digit, and/or inflammatory back pain; adverse prognostic factors: ≥5 active joints; or high functional impairment due to activity; or damage; or past glucocorticoid use. ^c^The treatment target is clinical remission or, if remission is unlikely to be achievable, at least low disease activity; clinical remission is the absence of signs and symptoms. Reproduced from Gossec et al. \[[@CR89]\]. Copyright © 2012 with permission from BMJ Publishing Group Ltd. *DMARD* disease-modifying anti-rheumatic drug, *MTX* methotrexate, *TNF* tumour necrosis factorTable 4Traditional disease-modifying anti-rheumatic drugs (DMARDs) and currently available biologics: clinical effects in psoriatic arthritis (PsA)DrugEvidence for beneficial impact on PsA (+ or −)Signs/symptomsRadiographic damage/progressionEnthesitisDactylitisAxial involvementMethotrexate \[[@CR105]--[@CR108]\]−InconclusiveUnknownUnknown−Sulfasalazine \[[@CR109]--[@CR111]\]+−−−−Leflunomide \[[@CR112]--[@CR114]\]+UnknownUnknownUnknown−Cyclosporine A \[[@CR115]--[@CR117]\]+UnknownUnknownUnknown−Biologics Anti-TNF-α antibodies \[[@CR2]\]++++Unknown^a^  Etanercept \[[@CR125], [@CR126]\]++++Unknown^a^  Infliximab \[[@CR118], [@CR119]\]++++Unknown^a^  Adalimumab \[[@CR120], [@CR121]\]++InconclusiveInconclusiveUnknown^a^  Golimumab \[[@CR122], [@CR123]\]++++Unknown^a^  Certolizumab pegol \[[@CR127], [@CR128]\]++++Unknown^a^ Anti-IL-12/23 antibody  Ustekinumab \[[@CR124], [@CR202]\]++++Unknown*IL* interleukin, *TNF* tumour necrosis factor^a^The efficacy of anti-TNF-α antibodies in axial involvement has not been directly evaluated in PsA trials. Treatment responses reported in ankylosing spondylitis are used to indicate efficacy in this condition \[[@CR129]\]

Traditional Treatments {#Sec8}
----------------------

Phototherapy, fumaric acid esters and systemic retinoids can be effective first-line strategies for psoriasis but do not improve signs and symptoms of PsA \[[@CR129]\]. Non-steroidal anti-inflammatory drugs (NSAIDs) are first-line treatment options for mild PsA and may improve joint symptoms \[[@CR89], [@CR129]\]. However, NSAIDs are not recommended for treatment of psoriasis, because they may worsen skin lesions \[[@CR130]--[@CR134]\]. Similarly, traditional regimens of systemic corticosteroids are not recommended for treatment of psoriasis, because clinical trial data are not available and because of their association with psoriasis flares during or after tapering \[[@CR129]\].

### Methotrexate {#Sec9}

Methotrexate is approved in the USA by the Food and Drug Administration (FDA) for severe, recalcitrant, disabling psoriasis and in the UK, Germany, France, Sweden and Spain for severe psoriasis. European approvals of methotrexate for treatment of concomitant psoriasis and PsA are limited. Although formal clinical evidence is lacking on the efficacy of methotrexate in PsA, it is commonly used as first-line therapy and in combination with biologics. Two randomized, placebo-controlled studies assessed the efficacy and safety of methotrexate in PsA patients; each study demonstrated significant improvements in global assessment ratings with active treatment \[[@CR105], [@CR106]\]. However, neither study showed a positive effect of methotrexate on the basis of objective measures such as tender and swollen joint counts \[[@CR105], [@CR106]\]. Methotrexate has not been conclusively found to have a positive impact on radiographic progression seen over 24 months \[[@CR107]\]. An observational cohort study, however, found a mild positive impact of methotrexate on PsA progression \[[@CR108]\].

Comparative studies between methotrexate and other treatments in psoriasis patients have generally shown greater efficacy with other treatment options, such as cyclosporine A \[[@CR135]\], adalimumab \[[@CR136]\] and briakinumab \[[@CR137]\]. Treatment with methotrexate has been associated with hepatic, pulmonary and bone marrow toxicity, as well as teratogenicity \[[@CR138]\]. Furthermore, in psoriasis patients with risk factors for liver disease, such as obesity (fatty liver) and alcoholism, the potential for transaminase elevation and liver pathology limits long-term use of methotrexate.

### Sulfasalazine {#Sec10}

Sulfasalazine is not approved by the FDA for the treatment of patients with psoriasis or PsA \[[@CR138]\]. Although the precise mechanism of action of sulfasalazine is unknown, it is thought to have anti-inflammatory effects mediated through inhibition of the 5-lipoxygenase pathway \[[@CR139]\]. Modest improvements in psoriasis have been reported in randomized, double-blind, controlled studies of sulfasalazine \[[@CR138], [@CR140]\]. Other studies have demonstrated the effectiveness of sulfasalazine in PsA \[[@CR109]--[@CR111], [@CR141]--[@CR143]\], with short-term data in one small study also showing dermatologic improvements \[[@CR110]\]. The impact of sulfasalazine on radiographic progression, however, has not been reported \[[@CR109]--[@CR111], [@CR141]--[@CR143]\]. Sulfasalazine has been associated with gastrointestinal intolerance, arthralgia, reversible oligospermia, leukopenia and agranulocytosis \[[@CR138]\].

### Leflunomide {#Sec11}

Leflunomide is a pyrimidine synthesis inhibitor and has been shown to inhibit T cell activation and proliferation \[[@CR144]\]. It is not approved by the FDA for psoriasis or PsA, but it is approved by the European Medicines Agency (EMA) for PsA. In randomized, double-blind, placebo-controlled studies of patients with both psoriasis and PsA, leflunomide improved skin and joint symptoms \[[@CR112]--[@CR114]\]. Leflunomide has been associated with gastrointestinal toxicity (e.g. diarrhoea and nausea), elevated liver enzymes, increased risk of infections and leukopenia \[[@CR138]\].

### Cyclosporine A {#Sec12}

Cyclosporine A is a potent immunosuppressant and is thought to act on the immune system at multiple pathways \[[@CR145]\]. It is approved by the FDA for severe, recalcitrant psoriasis on the basis of positive findings from a number of controlled clinical trials \[[@CR138], [@CR146]--[@CR152]\]. Three studies have also demonstrated the safety and modest efficacy of cyclosporine A in PsA \[[@CR115]--[@CR117]\]. Cyclosporine A has been associated with nephrotoxicity and hypertension \[[@CR138]\] and is recommended only for short-term use (up to 12 months).

### Biologics {#Sec13}

#### Anti-TNF-α Agents {#Sec14}

TNF-α plays a pivotal role in the chronic inflammation and aberrant immune responses that underlie psoriasis and PsA. Biologic agents that inhibit TNF-α, including a fusion protein, etanercept, and antibody-based treatments such as infliximab and adalimumab, are indicated for and have shown efficacy in psoriasis and PsA, including inhibition of radiographic progression \[[@CR2], [@CR118]--[@CR121], [@CR126], [@CR136], [@CR153]--[@CR155]\]. Golimumab, a newer human monoclonal antibody against TNF-α, is also indicated for and has shown efficacy in the treatment of PsA on the basis of positive findings from a 24-week, randomized, placebo-controlled study \[[@CR122]\] and from open-label extension studies \[[@CR123]\]. Golimumab is not approved by the FDA for treatment of psoriasis; however, clinical trial evidence suggests that this agent can have a positive effect on psoriatic skin lesions in patients with PsA \[[@CR122]\]. Certolizumab pegol (Cimzia^®^; UCB Pharma, Brussels, Belgium) is a human anti-TNF-α antibody conjugated with a 40 kDa polyethylene glycol molecule, which is administered subcutaneously. It is FDA approved for treatment of PsA and has received a recommendation for marketing authorization in Europe by the EMA Committee for Medicinal Products for Human Use \[[@CR156], [@CR157]\]. Because it contains only a single Fab′ of anti-TNF antibody and lacks an Fc′ portion, certolizumab pegol hypothetically may be less likely to induce antibody-related complement activation, apoptosis or cellular toxicity \[[@CR158]\]. Results from a randomized, double-blind phase II study of certolizumab pegol showed efficacy in patients with moderate to severe psoriasis \[[@CR158]\]. A phase III, multicentre, double-blind, parallel-group study in patients with PsA showed improvement in all PsA clinical domains, including skin manifestations and physical functioning at week 24 \[[@CR127], [@CR128]\]. Twenty percent of the study patients had previously experienced inadequate responses to an anti-TNF agent and, despite this, they demonstrated responses similar to those of the overall study population \[[@CR127]\]. Adverse events were consistent with those seen in other studies of certolizumab pegol.

The evidence surrounding anti-TNF agents and risk reduction of adverse cardiac events is not definitive. Data on the cardioprotectiveness of these agents in PsA are not currently available. A large retrospective Kaiser Permanente Southern California (KPSC) health plan study concluded that TNF inhibitor use in psoriasis was associated with a significantly reduced myocardial infarction risk, compared with topical treatment. Although the KPSC data show promising results, variables in the KPSC study, such as the use of age as a dichotomous variable in multivariate analyses and the lack of a longer TNF treatment duration, raise questions as to whether the use of age as a continuous variable or a longer study period would have impacted the findings \[[@CR159]\]. Additional studies are needed to further evaluate the cardioprotective effects of anti-TNF agents in both psoriasis and PsA.

#### Ustekinumab {#Sec15}

The anti-IL-12/23 monoclonal antibody ustekinumab is indicated for and has shown efficacy in psoriasis \[[@CR160], [@CR161]\]. In a phase II study of PsA, ustekinumab showed improvement in ACR response rates and significant improvement in skin disease, enthesitis, dactylitis and physical functioning \[[@CR124]\]. The study doses were higher than those used for managing psoriasis \[[@CR124], [@CR161]\]. Similar positive results were recently reported with ustekinumab in phase III studies in PsA patients who had previously received anti-TNF and DMARD treatment \[[@CR162], [@CR163]\]. Results from the Active Comparator (CNTO1275/Enbrel) Psoriasis Trial (ACCEPT) in psoriasis demonstrated that, compared with etanercept treatment, ustekinumab treatment resulted in greater improvement in efficacy parameters at week 12, including achievement of a 75 % improvement in the Psoriasis Area and Severity Index score (PASI 75; the primary endpoint), a Physician's Global Assessment (PGA) score of 0 or 1, and achievement of a 90 % improvement in the PASI score (PASI 90) \[[@CR164]\]. Of note, however, although greater efficacy was seen with ustekinumab, more than half of the patients in the etanercept group met the primary endpoint, and almost half obtained a PGA score of 0 or 1 \[[@CR164]\].

Direct comparison studies have not yet been conducted for many of the biologic therapies, which may make it difficult to determine whether one agent is more beneficial in treating specific patient symptoms. Overall, TNF agents may be a better choice than topical treatments when patients have extensive skin involvement, and the overuse of some topical agents and associated adverse effects may be of concern \[[@CR89]\]. Guidelines note that efficacy with etanercept may be lesser or delayed when it comes to PsA skin involvement. Although there have been no head-to-head comparison studies with etanercept in PsA, a comparison study in psoriasis demonstrated that at 12 weeks, treatment with ustekinumab resulted in superior efficacy in skin outcomes, compared with etanercept. With respect to joint involvement, no evident differences in efficacy have been observed among the various TNF inhibitors but, again, head-to-head comparison studies are not available \[[@CR89]\]. Although comparator studies can provide insight into the efficacy and safety of an agent in clinical trials, it is always important to remember the impact that individual patient characteristics can have on drug performance, thus highlighting the importance of an individualized approach to drug selection.

Biologics have a number of limitations for patients with psoriasis and PsA. A substantial proportion of patients with psoriasis or PsA do not have a sustained response to TNF-α inhibitors \[[@CR165], [@CR166]\]. In addition, some biologics, such as infliximab, are dosed intravenously, which can be inconvenient for patients. Loss of response over time, cost and safety issues affect decisions to use nonbiologic and biologic DMARDs over the long term \[[@CR167], [@CR168]\]. An unmet need exists for an efficacious, well-tolerated, safe and easy-to-use treatment option for patients with psoriasis and PsA that improves both skin and joint disease.

### Combination Therapy {#Sec16}

The available treatment algorithms put forth by the American Academy of Dermatology (AAD) \[[@CR101]\], GRAPPA \[[@CR129]\] and EULAR \[[@CR89]\] position combination therapy with a DMARD/TNF inhibitor or DMARD/other biologic as treatment for moderate or severe PsA in patients who still have symptoms after conventional DMARD use. Minimal literature on the effectiveness of biologic combination therapy is available, warranting the need for studies evaluating the combination of two biologics for PsA \[[@CR169]--[@CR173]\]. The EULAR guidelines further note that clinical trials to date have not shown superiority with combination use of TNF inhibitors and synthetic DMARDs versus TNF inhibitor monotherapy, and additional trials are needed \[[@CR89]\].

New and Future Treatment Options {#Sec17}
================================

PDE4 Inhibition {#Sec18}
---------------

The large PDE enzyme family is the sole route for enzymatic degradation of cAMP, an intracellular secondary messenger, which controls a wide array of cellular functions \[[@CR174]\]. Apremilast is an orally available small molecule, which specifically inhibits the activity of PDE4, an isoform found predominantly in immune cells such as monocytes, T cells and neutrophils \[[@CR174]\]. By inhibiting PDE4-mediated breakdown of cAMP, apremilast works intracellularly to regulate inflammatory mediators that are considered to play an important role in the pathogenesis of psoriasis and PsA \[[@CR175], [@CR176]\].

### Apremilast {#Sec19}

Phase II studies of apremilast have demonstrated efficacy in patients with psoriasis and PsA. In one study, apremilast 20 or 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis over 24 weeks and improved pruritus \[[@CR177]\]. In another study, apremilast 20 mg twice daily or 40 mg once daily improved the signs and symptoms of PsA over 24 weeks \[[@CR178]\]. In both studies, apremilast was generally well tolerated; the majority (\>90 %) of treatment-related adverse events in the clinical studies were mild to moderate and did not lead to study discontinuation \[[@CR177], [@CR178]\]. The most common treatment-related adverse events were headache, nausea, diarrhoea, nasopharyngitis, fatigue and upper respiratory tract infection \[[@CR177], [@CR178]\]. No opportunistic infections were reported \[[@CR177], [@CR178]\].

Apremilast is currently being studied in phase III clinical trial programmes for psoriasis and PsA; additional studies are assessing its efficacy in ankylosing spondylitis, Behçet's disease and RA. The Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) programme is assessing the use of apremilast in patients with moderate to severe plaque psoriasis in two 52-week, randomized, placebo-controlled trials with long-term, open-label extensions. Preliminary results from ESTEEM 1 have demonstrated the clinical efficacy of apremilast in significantly reducing the severity of moderate to severe psoriasis and its effectiveness in difficult-to-treat areas such as the nails and scalp. In addition, apremilast was generally well tolerated, with no new safety or laboratory findings \[[@CR179], [@CR180]\]. The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) programme is assessing the effects of apremilast on the signs and symptoms of PsA in four randomized, placebo-controlled trials with long-term, open-label extensions. PALACE 3 is evaluating the efficacy and safety of apremilast in patients with PsA and a qualifying psoriasis lesion. Preliminary results from PALACE 1 have confirmed the clinical efficacy of apremilast in patients with PsA who have prior experience with traditional and biologic DMARDs, with no new safety signals and improved tolerability, compared with the results of phase II studies \[[@CR181], [@CR182]\].

JAK Inhibitors {#Sec20}
--------------

Janus kinase (JAK) inhibitors serve as intracellular signal transduction molecules linked to surface receptors for multiple pro-inflammatory cytokines, including IL-21, which are crucial for T cell activation and functioning. Tofacitinib is a small-molecule inhibitor of JAK1, JAK3 and, to a lesser extent, JAK2, and is administered orally \[[@CR183]\]. Tofacitinib 5 mg twice daily is approved in the USA for patients with RA who are unresponsive to DMARDs. With tofacitinib, JAK inhibition may interrupt key components of the immune and inflammatory responses that underlie both psoriasis and PsA. Tofacitinib has shown efficacy across various parameters in RA \[[@CR183]--[@CR185]\]. The potential role of tofacitinib in treatment of psoriasis patients is not yet known; however, in a phase I, randomized, controlled, dose-ranging study, tofacitinib was effective in patients with psoriasis \[[@CR186]\]. Similarly, in a 12-week, phase IIb, double-blind, placebo-controlled study, tofacitinib (2, 5 and 15 mg twice daily) was effective in treatment of patients with moderate to severe plaque psoriasis \[[@CR187]\]. Decreases in mean neutrophil counts and haemoglobin values and increases in lipoprotein levels were observed \[[@CR187]\]. Phase III studies with tofacitinib 5 and 10 mg twice daily are ongoing in patients with moderate to severe plaque psoriasis. No clinical efficacy and safety data for PsA are available but, on the basis of the results in RA and psoriasis, evaluation of tofacitinib in PsA is warranted.

Anti-IL-17 Agents {#Sec21}
-----------------

IL-17 is a pro-inflammatory cytokine involved in the pathogenesis of psoriasis and PsA, as well as in other immune-mediated chronic inflammatory disorders. As such, it has been the object of intense drug development efforts, and a number of biologic agents targeting this molecule are being investigated in clinical studies of psoriasis and PsA.

### Secukinumab {#Sec22}

Secukinumab (AIN-457; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is a fully human, targeted monoclonal antibody against IL-17a, and is administered subcutaneously or intravenously \[[@CR188], [@CR189]\]. Preliminary results from phase II studies of secukinumab have shown efficacy in psoriasis with 150 mg subcutaneous regimens, 3 × 75 mg and 3 × 150 mg subcutaneous doses and 3 mg/kg, 10 mg/kg and 3 × 10 mg/kg intravenous doses \[[@CR188], [@CR189]\]. With subcutaneous administration of secukinumab, the rates of serious adverse events and infections were comparable to those observed with placebo \[[@CR188], [@CR189]\]. Phase III trials of secukinumab for psoriasis (ClinicalTrials.gov study identifier NCT01365455) and PsA (ClinicalTrials.gov study identifier NCT01392326) are under way. Data are limited on the clinical efficacy and safety of secukinumab in PsA. A short-term phase II proof-of-concept study supported a significant phase III programme, which is currently under way \[[@CR190]\].

### Brodalumab {#Sec23}

Brodalumab (AMG 827; Amgen, Thousand Oaks, CA, USA) is a fully human monoclonal antibody, which binds to the IL-17 receptor and blocks IL-17 signalling \[[@CR191]\]. Brodalumab binds with high affinity to human IL-17RA and blocks the biologic activity of IL-17A, IL-17F, IL-17A/F heterodimer and IL-17E (IL-25). A phase II study of subcutaneous brodalumab demonstrated efficacy in patients with moderate to severe psoriasis \[[@CR191]\]. Brodalumab has also demonstrated efficacy in PsA in a phase II study, with similar efficacy noted in anti-TNF-experienced and -inexperienced patients \[[@CR192]\]. Given these positive results, phase III studies of brodalumab in patients with psoriasis are under way (ClinicalTrials.gov study identifiers NCT01708603 and NCT01708629).

### Ixekizumab {#Sec24}

Ixekizumab (LY2439821; Eli Lilly and Company, Indianapolis, IN, USA) is a humanized anti-IL-17A monoclonal antibody, which is administered subcutaneously. In a phase II study, ixekizumab improved clinical symptoms in patients with moderate to severe psoriasis \[[@CR193]\]. Phase III studies of ixekizumab in psoriasis (ClinicalTrials.gov study identifier NCT01474512) and PsA (ClinicalTrials.gov study identifier NCT01695239) are ongoing; no data are yet available with this agent in patients with PsA.

Protein Kinase C Inhibitor {#Sec25}
--------------------------

Protein kinase C isoforms are important for activation and proliferation of T cells, as well as for antigen receptor function \[[@CR194]\]. Activated T cells are considered central to the psoriatic disease process \[[@CR194]\]. Sotrastaurin (AEB071; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is a protein kinase C inhibitor, which is administered orally. Sotrastaurin has strong and specific activity on PKCθ, PKCα and PKCβ, and lesser activity on PKCδ, PKCε and PKCη \[[@CR194]\]. Preliminary phase II proof-of-concept data suggest its efficacy in psoriasis \[[@CR194]\]; additional phase II study results are expected. No clinical efficacy and safety data in PsA are available.

Other Mechanisms {#Sec26}
----------------

### CF101 {#Sec27}

Adenosine A3 receptors are over-expressed in peripheral blood mononuclear cells in patients with psoriasis, RA and Crohn's disease \[[@CR195]\]. CF101 (Can-Fite BioPharma, Petah Tikva, Israel) is an oral adenosine A3 receptor inhibitor, which has been shown in preclinical investigations to decrease production of pro-inflammatory cytokines, including TNF-α and nuclear factor kappa B (NF-κB), and to induce inflammatory cell apoptosis, leading to a broad anti-inflammatory effect \[[@CR195]\]. In a phase II, randomized, double-blind, dose-ranging, placebo-controlled study, CF101 showed progressive improvement over 12 weeks in the mean change from baseline in the PASI score, compared with placebo, in patients with plaque psoriasis \[[@CR195]\].

Additional investigational treatments for psoriasis and PsA in phase II studies are summarized in Table [5](#Tab5){ref-type="table"} \[[@CR158], [@CR177], [@CR178], [@CR181], [@CR186], [@CR187], [@CR191], [@CR193], [@CR195]--[@CR200]\].Table 5Summary of new and emerging treatments in psoriasis and psoriatic arthritis (PsA)MOADrugManufacturerTrial phase completed^a^Ongoing trials^a^Preliminary efficacy dataPDE4 inhibitorApremilastCelgenePhase II, IIIPhase III\
ESTEEM (psoriasis), PALACE (PsA)Psoriasis \[[@CR177]\]\
PsA \[[@CR178], [@CR181]\]JAKTofacitinibPfizerPhase IIPhase III psoriasis + PsA (NCT01519089)Psoriasis \[[@CR186], [@CR187]\]Anti-IL-17 agentsSecukinumab (AIN-457)NovartisPhase IIPhase III\
Psoriasis (NCT01365455)\
PsA (NCT01392326)Psoriasis \[[@CR196]--[@CR198]\]Brodalumab (AMG 827)AmgenPhase IIPhase III\
Psoriasis (NCT01708603 and NCT01708629)Psoriasis \[[@CR191]\]\
PsA \[[@CR192]\]Ixekizumab (LY2439821)Eli LillyPhase IIPhase III\
Psoriasis (NCT01474512)\
PsA (NCT01695239)Psoriasis \[[@CR193]\]Protein kinase C inhibitorSotrastaurin (AEB071)NovartisPhase IINonePsoriasis \[[@CR194]\]Adenosine A3 receptor inhibitorCF101Can-Fite BioPharmaPhase IIPhase II/III\
Psoriasis (NCT01265667)Psoriasis \[[@CR195]\]Calcineurin inhibitorVoclosporin (ISA247)IsotecknikaPhase IIINonePsoriasis \[[@CR200]\]Additional compounds in development for psoriasis or RA JAK1, JAK2 inhibitorLY3009104 (INCB28050, INCYTE)Eli LillyPhase IIb study ongoing in psoriasis (NCT01490632) JAK3 inhibitorVX-509Vertex Pharmaceuticals JAK inhibitorASP015KAstellas PharmaPhase IIa trial in psoriasis completed (NCT01096862)In phase IIb development for RA IL-12/IL-23 synthesis inhibitorAplimod (STA-5326)Synta Pharmaceuticals IL-23 blockerSCH 900222MerckPhase II trial in psoriasis completed (NCT01225731)Phase III trial in psoriasis planned (NCT01722331) Regulatory T cell activatorBT-061BiotestPhase II trial in psoriasis completed (NCT01072383)Phase II trial in RA ongoing (NCT01481493) S1P1 receptor blockerACT-128800Actelion p38 MAPK blockerBMS-582949Bristol-Myers SquibbPhase I/II trial in psoriasis completed; patent filed in 2012 for treatment of RA (see <http://www.highbeam.com/doc/1P3-2609565631.html>) Fumaric acidFP187Forward-PharmaCurrently in phase II development for psoriasis (see <http://www.forward-pharma.com/about_us.html>) Anti-inflammatory (MOA proprietary)LEO22811LEO PharmaCurrently in phase II development for 'inflammatory indications' (see <http://www.leo-pharma.us/Home/Research-and-Development/LEO-Pharma-Global-Pipeline.aspx>) Sirtuin activatorSRT2104GlaxoSmithKlinePhase II study in psoriasis complete (NCT01154101) Oxidized phospholipidVB-201VBL TherapeuticsPhase II study in psoriasis complete (NCT01001468)*ESTEEM* Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis, *IL* interleukin, *JAK* Janus kinase, *MAPK* mitogen-activated protein kinase, *MOA* mechanism of action, *PALACE* Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy, *PDE* phosphodiesterase, *RA* rheumatoid arthritis, *S1P1* sphingosine-1-phosphate receptor 1^a^The NCT numbers are ClinicalTrials.gov study identifiers

Conclusions {#Sec28}
===========

Psoriatic arthritis is a chronic and progressive inflammatory arthritis closely associated with psoriasis and can lead to significant morbidity. Dermatologists who treat psoriasis patients are able to regularly and routinely screen for early PsA by asking about possible joint pain, stiffness or tenderness. Rapid screening questionnaires may also help in identifying early PsA. In patients with suspected PsA, dermatologists who are familiar with the distinguishing clinical features of PsA and the current diagnostic CASPAR can conduct a more thorough evaluation. Depending on their comfort level in dealing with joint symptoms, dermatologists may gauge PsA severity and the risk of progression and initiate treatment. Optimal interventions for active PsA should aim to control skin and joint signs and symptoms. For patients with more severe or complicated symptoms, dermatologists and rheumatologists must collaborate to adequately manage both skin and joint psoriatic involvement over the long term.
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